Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
CHAPEL HILL, N.C., March 29, 2017 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases, today announced it will participate in the 16th Annual Needham & Company Healthcare Conference. Management is scheduled to present at 3:00 p.m. ET on Wednesday, April 5, 2017 in New York.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin has been evaluated in two phase 3 clinical trials for community-acquired bacterial pneumonia (CABP). Cempra is currently seeking approval for both intravenous and oral capsule formulations from the U.S. Food and Drug Administration. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Cempra is contracted with BARDA for the development of solithromycin for pediatric use and has commenced enrollment in a global Phase 2/3 trial to evaluate the safety and efficacy of solithromycin versus standard of care antibiotics in children and adolescents from two months to 17 years of age. Solithromycin is also in development for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Fusidic acid is Cempra's second product candidate, which has completed a phase 3 trial comparing fusidic acid to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI). Cempra also has an ongoing exploratory study of fusidic acid for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is also studying solithromycin for ophthalmic conditions and has synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Company Contact: John Bluth Cempra, Inc. +1 984 209 4534 [email protected]
